Journal of Investigative Medicine · 2007 · 27 citations · 32 references
Life SciencesGeneticsOncologyCancer GeneticsMedical GeneticsMolecular OncologyGenotype-phenotype Association AnalysisVariant InterpretationBreast Cancer PrognosisEnzyme Gene VariantsGenotype VariationInsertion-deletion Polymorphism MarkersInsertion-deletion VariantsInsertion-deletion VariationPrognostic Factors AnalysisTumor Size Prognosis
The aims of the present study were to investigate the distribution of the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene in breast cancer patients and the association between ACE genotypes and clinicopathologic features, as well as their effects on prognosis. We assessed the I/D polymophism of the ACE gene by using polymerase chain reaction from peripheral blood in breast cancer and healthy age-matched women. The clinicopathologic parameters of breast cancer patients were obtained from medical records. Of the 57 patients, 31 (54.4%) had DD, 24 (42.1%) had ID, and 2 (3.5%) had II genotypes. In control subjects, 33 (63.5%) had DD, 12 (23.1%) had ID, and 7 (13.4%) had II genotypes. The ID genotype was seen more commonly in breast cancer patients (p = .03). When the combination of ID and II genotypes was used as a reference group, the DD genotype was associated with negative hormone receptor status (p = .003), tumor size (p = .054), and lymph node involvement (p = .07) but not histologic high grade and c-erb B2 overexpression. These results suggest that the DD genotype may accompany poor prognostic factors and influence the tumor course.
32
Brigitte Rigat, C. Hübert, F Alhenc‐Gelas et al. · Journal of Clinical Investigation · 1990 · 3.8K citations · Full text
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
Anthony F. Lever, David Hole, C. Gillis et al. · The Lancet · 1998 · 547 citations
Medicine, Oncology, Pharmacology +8